Triple-negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Markers with Anti-miRNA: A Systematic Review and Meta-Analysis

Background and aim: The present study is the first systematic review and meta-analysis study conducted to investigate the effectiveness of anti-miRNA for triple-negative breast cancer therapy using RNA nanoparticles targeting Stem Cell markers.Material and methods: The Present study is a systematic review and meta-analysis based on PRISMA 2020 Checklist. A search of PubMed, Scopus, Web of Science, EBSCO, ISI Web of Knowledge, and Embase databases was conducted until April 2023 in order to identify systematic literature. The 95% confidence intervals for effect size have been calculated using the fixed effect model and the inverse-variance method, respectively. A meta-analysis was conducted using Stata/MP v.17.Results: An initial review was conducted by eliminating duplicate studies, reviewing 103 abstracts, and reviewing the full text of 11 studies by two authors. Finally, two studies were selected. The average hydrodynamic diameter of 3WJ/CD133apt/anti-miR21 nanoparticles was 10.30 nm (ES, 10.30 nm 95% CI 7.10 nm, 13.51nm) with low heterogeneity (I2=0%; P =0.86). Zeta potential was determined to be -25.19 mV (ES, -25.19 mV 95% CI -39.57 mV, -10.81 mV).Conclusions: 3WJ/CD133apt/anti-miR21 nanoparticles can be considered a suitable option for selecting a Triple-negative breast cancer treatment (TNBC).